Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept

  • Published:
Quality of Life Research Aims and scope Submit manuscript

Abstract

Purpose

To assess health-related quality of life (HR-QoL) in patients with Rheumatoid arthritis (RA), early RA and early psoriatic arthritis (PsA), and to evaluate the efficacy of etanercept in reducing disability.

Methods

Twenty healthy volunteers, 40 RA, 20 early RA and 20 early PsA patients were recruited. All patients received etanercept plus methotrexate. Assessments at baseline and after 2 years’ therapy included Disease Activity Scores on 44 joints [DAS44], Health Assessment Questionnaire (HAQ) scores and Short Form-36 (SF-36) scores.

Results

HAQ and SF-36 scores were significantly worse in patients with RA, early RA or early PsA than in healthy volunteers. The HAQ score at baseline was significantly higher in RA patients than in patients with early RA or early PsA, whereas the scores were similar in patients with early RA and early PsA. Patients with early RA had greater impairment than patients with early PsA in several areas of disability. After 2 years’ treatment, HAQ scores and SF-36 summary and subscale scores improved significantly in the three patient groups.

Conclusions

This study suggests that early PsA is a less disabling disease than RA or early RA. It confirms the efficacy of etanercept in reducing disease severity and improving HR-QoL and suggests that early therapeutic intervention may lead to greater improvement in the mental and emotional components of these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Woolacott, N. F., Khadjesari, Z. C., Bruce, I. N., et al. (2006). Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review. Clinical and Experimental Rheumatology, 24, 587–593.

    CAS  PubMed  Google Scholar 

  2. Kane, D., Stafford, L., Bresnihan, B., et al. (2003). A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford), 42, 1460–1468.

    Article  CAS  Google Scholar 

  3. Smolen, J. S., Aletaha, D., Machold, K. P., et al. (2005). Therapeutic strategies in early rheumatoid arthritis. Bailliere’s Best Practice and research Clinical Rheumatology, 19, 163–177.

    Article  CAS  Google Scholar 

  4. Mease, P. J., Kivitz, A. J., Burch, F. X., et al. (2004). Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis and Rheumatism, 50, 2264–2272.

    Article  CAS  PubMed  Google Scholar 

  5. Wick, M. C., Lindblad, S., Weiss, R. J., et al. (2005). Estimated prediagnosis radiological progression: An important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases, 64, 134–137.

    Article  CAS  PubMed  Google Scholar 

  6. Genovese, M. C., Bathon, J. M., Martin, R. W., et al. (2002). Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes [see comment]. Arthritis and Rheumatism, 46, 1443–1450.

    Article  CAS  PubMed  Google Scholar 

  7. Donahue, K. E., Gartlehner, G., Jonas, D. E., et al. (2008). Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Annals of Internal Medicine, 148, 124–134.

    PubMed  Google Scholar 

  8. World Health Organization. World Health Organization: classification of impairments, disabilities and handicaps. Geneva: WHO, 1980.

  9. Ware, J. E, Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483.

    Article  PubMed  Google Scholar 

  10. Wolfe, F. (2000). A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis and Rheumatism, 43, 2751–2761.

    Article  CAS  PubMed  Google Scholar 

  11. Bruce, B., & Fries, J. F. (2005). The health assessment questionnaire (HAQ). Clinical and Experimental Rheumatology, 23, S14–S18.

    CAS  PubMed  Google Scholar 

  12. West, E., Jonsson, S. W., West, E., et al. (2005). Health-related quality of life in rheumatoid arthritis in Northern Sweden: A comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clinical Rheumatology, 24, 117–122.

    Article  PubMed  Google Scholar 

  13. Sokoll, K. B., & Helliwell, P. S. (2001). Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. Journal of Rheumatology, 28, 1842–1846.

    CAS  PubMed  Google Scholar 

  14. Borman, P., Toy, G. G., Babaoglu, S., et al. (2007). A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clinical Rheumatology, 26, 330–334.

    Article  PubMed  Google Scholar 

  15. Fransen, J., & van Riel, P. (2009). The disease activity score and the EULAR response criteria. Rheumatic Diseases Clinics of North America, 35(4), 745–757.

    Article  PubMed  Google Scholar 

  16. Arnett, F. C., Edworthy, S. M., Bloch, D. A., et al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism, 31, 315–324.

    Article  CAS  PubMed  Google Scholar 

  17. Moll, J. M., & Wright, V. (1973). Psoriatic arthritis. Seminars in Arthritis and Rheumatism, 3, 55–78.

    Article  CAS  PubMed  Google Scholar 

  18. Langley, R. G., & Ellis, C. N. (2004). Evaluating psoriasis with Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA) and Lattice System Psoriasis Global Assessment (LS-PGA). Journal of the American Academy of Dermatology, 51, 563–569.

    Article  PubMed  Google Scholar 

  19. Husted, J. A., Gladman, D. D., Farewell, V. T., Long, J. A., & Cook, R. J. (2007). Validating the SF-36 health questionnaire in patients with psoriatic arthritis. Journal of Rheumatology, 24, 511–517.

    Google Scholar 

  20. Kvien, T. K., Kaasa, S., & Smedstad, L. M. (1998). Performance of the norwegian SF-36 health survey in patients in patients with rheumatoid arthritis A comparison of the SF-36 with disease specific measures. Journal of Clinical Epidemiology, 51, 1077–1086.

    Article  CAS  PubMed  Google Scholar 

  21. Husted, J. A., Gladman, D. D., Farewell, V. T., et al. (2001). Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 45, 151–158.

    Article  CAS  PubMed  Google Scholar 

  22. Van der Heijde, D., Klareskog, L., Rodriguez-Valverde, V., et al. (2006). Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and Rheumatism, 54, 1063–1074.

    Article  PubMed  Google Scholar 

  23. Moreland, L. W., Weinblatt, M. E., Keystone, E. C., et al. (2006). Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. Journal of Rheumatology, 33, 854–861.

    CAS  PubMed  Google Scholar 

  24. Genovese, M. C., Bathon, J. M., Fleischmann, R. M., et al. (2005). Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Journal of Rheumatology, 32, 1232–1242.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Sohita Dhillon of Wolters Kluwer Health who provided medical writing services on behalf of Wyeth Pharmaceuticals. The authors declare no conflict of interest directly relevant to this study.

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Rheumatology, S. Andrea University Hospital, “Sapienza” University of Rome, II School of Medicine, Via di Grottarossa 1039, 00189, Rome, Italy

    Andrea Picchianti-Diamanti, Valentina Germano, Claudia Ferlito, Raffaele D’Amelio & Bruno Laganà

  2. Unit of Rheumatology, S. Peter Hospital FBF, Research Center, S. Pietro AfaR, Rome, Italy

    Alberto Migliore

Authors
  1. Andrea Picchianti-Diamanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Germano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudia Ferlito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alberto Migliore
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raffaele D’Amelio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruno Laganà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Picchianti-Diamanti.

Additional information

The authors Andrea Picchianti Diamanti and Valentina Germano contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Picchianti-Diamanti, A., Germano, V., Ferlito, C. et al. Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept. Qual Life Res 19, 821–826 (2010). https://doi.org/10.1007/s11136-010-9651-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-010-9651-3

Keywords

Search

Navigation